{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:07:45Z","timestamp":1787062065828,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ejmech.2011.10.010","type":"journal-article","created":{"date-parts":[[2011,10,16]],"date-time":"2011-10-16T05:00:10Z","timestamp":1318741210000},"page":"5978-5990","source":"Crossref","is-referenced-by-count":14,"title":["Triazole ring-opening leads to the discovery of potent nonsteroidal 17\u03b2-hydroxysteroid dehydrogenase type 2 inhibitors"],"prefix":"10.1016","volume":"46","author":[{"given":"Kuiying","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseen A.","family":"Al-Soud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf W.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marchais-Oberwinkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2011.10.010_bib1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1359\/jbmr.1998.13.5.763","article-title":"A\u00a0unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men","volume":"13","author":"Riggs","year":"1998","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2011.10.010_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ejca.2005.10.028","article-title":"Effects of third-generation aromatase inhibitors on bone","volume":"42","author":"McCloskey","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2011.10.010_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1152\/physrev.2001.81.1.419","article-title":"Sex steroids and bone","volume":"81","author":"Compston","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2011.10.010_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/JCI118382","article-title":"Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women","volume":"97","author":"Slemenda","year":"1996","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2011.10.010_bib5","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1172\/JCI119701","article-title":"Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens","volume":"100","author":"Slemenda","year":"1997","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2011.10.010_bib6","first-page":"275","article-title":"Skeletal effects of estrogen","volume":"15","author":"Turner","year":"1994","journal-title":"Endocr.\u00a0Rev."},{"key":"10.1016\/j.ejmech.2011.10.010_bib7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM198711053171901","article-title":"Hip fracture and the use of estrogens in postmenopausal women. The Framingham study","volume":"317","author":"Kiel","year":"1987","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2011.10.010_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00000441-199701000-00002","article-title":"Estrogen therapy and osteoporosis: principles & practice","volume":"313","author":"Notelovitz","year":"1997","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ejmech.2011.10.010_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2003-0003","article-title":"Androgens and bone","volume":"25","author":"Vanderschueren","year":"2004","journal-title":"Endocr.Rev."},{"key":"10.1016\/j.ejmech.2011.10.010_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/MED.0b013e3282fe6ca9","article-title":"Androgens and bone","volume":"15","author":"Vanderschueren","year":"2008","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.ejmech.2011.10.010_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1677\/erc.0.0060175","article-title":"Serum oestradiol and breast cancer risk","volume":"6","author":"Key","year":"1999","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejmech.2011.10.010_bib12","doi-asserted-by":"crossref","first-page":"12964","DOI":"10.1016\/S0021-9258(18)31480-7","article-title":"Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity","volume":"268","author":"Wu","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib13","doi-asserted-by":"crossref","first-page":"22123","DOI":"10.1074\/jbc.M111726200","article-title":"Purification, reconstitution, and steady-state kinetics of the trans-membrane 17 beta-hydroxysteroid dehydrogenase 2","volume":"277","author":"Lu","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1359\/jbmr.1998.13.10.1539","article-title":"17Beta-hydroxysteroid dehydrogenases in human bone cells","volume":"13","author":"Dong","year":"1998","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2011.10.010_bib15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/(SICI)1097-4644(19991201)75:3<528::AID-JCB16>3.0.CO;2-3","article-title":"Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function","volume":"75","author":"Janssen","year":"1999","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2174\/187152009788680000","article-title":"Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases","volume":"9","author":"Poirier","year":"2009","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jsbmb.2010.12.013","article-title":"17\u03b2-Hydroxysteroid dehydrogenases (17\u03b2-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development","volume":"125","author":"Marchais-Oberwinkler","year":"2011","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2011.10.010_bib18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ejmech.2008.03.020","article-title":"Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities","volume":"44","author":"Bydal","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0303-7207(00)00427-5","article-title":"Inhibitors of type II 17beta-hydroxysteroid dehydrogenase","volume":"171","author":"Poirier","year":"2001","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2011.10.010_bib20","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1021\/jm00022a018","article-title":"Steroidal spiro-gamma-lactones that inhibit 17 beta-hydroxysteroid dehydrogenase activity in human placental microsomes","volume":"38","author":"Sam","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0968-0896(98)00260-0","article-title":"Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative\/antiproliferative activities","volume":"7","author":"Tremblay","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.tetlet.2005.01.003","article-title":"4,5-Disubstituted cis-pyrrolidinones as inhibitors of 17\u03b2-hydroxysteroid dehydrogenase II. Part 1: synthetic approach","volume":"46","author":"Cook","year":"2005","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2011.10.010_bib23","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.bmcl.2005.04.025","article-title":"4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR","volume":"15","author":"Gunn","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2011.10.010_bib24","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1016\/j.bmcl.2006.06.041","article-title":"4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate","volume":"16","author":"Wood","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2011.10.010_bib25","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.bmc.2010.12.013","article-title":"17\u03b2-HSD2 inhibitors for the treatment of osteoporosis: identification of a promising scaffold","volume":"19","author":"Wetzel","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib26","first-page":"267","article-title":"Effect of 17beta-hydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys","volume":"8","author":"Bagi","year":"2008","journal-title":"J.\u00a0Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.ejmech.2011.10.010_bib27","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.1021\/jm058042r","article-title":"Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach","volume":"48","author":"Cavalli","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ardp.19963290506","article-title":"Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17, and P450 TxA2","volume":"329","author":"Hartmann","year":"1996","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2011.10.010_bib29","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1021\/jm950377t","article-title":"Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17","volume":"39","author":"W\u00e4chter","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib30","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.1021\/jm0503704","article-title":"Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis","volume":"48","author":"Voets","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib31","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1021\/jm800377h","article-title":"Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity","volume":"51","author":"Heim","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib32","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.1021\/jm800683c","article-title":"Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach","volume":"51","author":"Lucas","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib33","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1021\/jm101470k","article-title":"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives","volume":"54","author":"Lucas","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/ml100071j","article-title":"First selective CYP11B1 inhibitors for the treatment of cortisol-dependent diseases","volume":"2","author":"Hille","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2011.10.010_bib35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/ml100283h","article-title":"Optimization of the first selective steroid-11\u03b2-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases","volume":"2","author":"Hille","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2011.10.010_bib36","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1021\/jm800355c","article-title":"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer","volume":"51","author":"Pinto-Bazurco Mendieta","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib37","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.ejmech.2009.01.002","article-title":"Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls","volume":"44","author":"Hille","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0960-0760(03)00070-0","article-title":"Effects of novel 17alpha-hydroxylase\/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in\u00a0vitro and in\u00a0vivo","volume":"84","author":"Haidar","year":"2003","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2011.10.010_bib39","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.bmc.2007.10.094","article-title":"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure","volume":"16","author":"Jagusch","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib40","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0960-894X(99)00234-6","article-title":"N-substituted 4-(5-indolyl) benzoic acids. Synthesis and evaluation of steroid 5alpha-reductase type I and II inhibitory activity","volume":"9","author":"Baston","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2011.10.010_bib41","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0223-5234(00)01167-3","article-title":"6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5alpha reductases types 1 and 2","volume":"35","author":"Baston","year":"2000","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib42","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0968-0896(00)00070-5","article-title":"Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2","volume":"8","author":"Picard","year":"2000","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0968-0896(01)00293-0","article-title":"5-Phenyl substituted 1-methyl-2-pyridones and 4\u2032-substituted biphenyl-4-carboxylic acids. synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2","volume":"10","author":"Picard","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib44","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1021\/jm701447v","article-title":"Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases","volume":"51","author":"Frotscher","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib45","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1021\/jm800367k","article-title":"Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics","volume":"51","author":"Marchais-Oberwinkler","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib46","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1016\/j.bmc.2008.04.073","article-title":"Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases","volume":"16","author":"Bey","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib47","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1021\/jm8006917","article-title":"Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1)","volume":"51","author":"Bey","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.mce.2008.09.012","article-title":"The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1 and type 2","volume":"301","author":"Al-Soud","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2011.10.010_bib49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.mce.2008.09.024","article-title":"Structure-activity study in the class of 6-(3\u2032-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors","volume":"301","author":"Marchais-Oberwinkler","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2011.10.010_bib50","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.crci.2009.05.005","article-title":"Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations","volume":"12","author":"Kruchten","year":"2009","journal-title":"Comptes Rendus Chim."},{"key":"10.1016\/j.ejmech.2011.10.010_bib51","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jsbmb.2009.02.006","article-title":"Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells","volume":"114","author":"Kruchten","year":"2009","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2011.10.010_bib52","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1021\/jm901195w","article-title":"New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity","volume":"52","author":"Bey","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib53","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1016\/j.bmc.2010.03.065","article-title":"Novel estrone mimetics with high 17beta-HSD1 inhibitory activity","volume":"18","author":"Oster","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib54","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cmdc.201000457","article-title":"Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17\u2009\u03b2-hydroxysteroid dehydrogenase Type 1 (17\u2009\u03b2-HSD1): the role of the bicyclic moiety","volume":"6","author":"Oster","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2011.10.010_bib55","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1021\/jm101073q","article-title":"Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 1 (17\u03b2-HSD1) for the treatment of estrogen-dependent diseases","volume":"53","author":"Oster","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib56","doi-asserted-by":"crossref","first-page":"e12026","DOI":"10.1371\/journal.pone.0012026","article-title":"Insights in 17beta-HSD1 enzyme kinetics and ligand binding by dynamic motion investigation","volume":"5","author":"Negri","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejmech.2011.10.010_bib57","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm1009082","article-title":"New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17\u03b2-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases","volume":"54","author":"Marchais-Oberwinkler","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2011.10.010_bib58","unstructured":"Y.A. Al-Soud, S. Marchais-Oberwinkler, P. Kruchten, M. Frotscher, R.W. Hartmann, Synthesis and biological evaluation of hydroxyphenyl substituted 1,2,4-triazoles as non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenases, Arch. Pharm, submitted for publication."},{"key":"10.1016\/j.ejmech.2011.10.010_bib59","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.mce.2008.09.035","article-title":"Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents","volume":"301","author":"Kruchten","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2011.10.010_bib60","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cbic.200301023","article-title":"Fluorine in medicinal chemistry","volume":"5","author":"B\u00f6hm","year":"2004","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2011.10.010_bib61","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1126\/science.1131943","article-title":"Fluorine in pharmaceuticals: looking beyond intuition","volume":"317","author":"M\u00fcller","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2011.10.010_bib62","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1210\/en.2006-0113","article-title":"Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding","volume":"147","author":"Zhu","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2011.10.010_bib63","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1096\/fj.02-0026fje","article-title":"A\u00a0concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity","volume":"16","author":"Qiu","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2011.10.010_bib64","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1210\/me.11.13.1971","article-title":"Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha\/17 beta-HSD activity and cellular distribution","volume":"11","author":"Lin","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2011.10.010_bib65","first-page":"157","article-title":"C16 and C17 derivatives of estradiol as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships","volume":"15","author":"Sam","year":"1998","journal-title":"Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2011.10.010_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsbmb.2004.12.018","article-title":"2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor alpha","volume":"94","author":"Zimmermann","year":"2005","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523411007276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523411007276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T23:36:09Z","timestamp":1639179369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523411007276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0223523411007276"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2011.10.010","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}